TSHATaysha Gene Therapies, Inc.
What is the market doing?
No clear lean: nothing decisive, though heavily shorted (+14% of shares).
Rangebound, no clear trend. Price is −16% vs its 200-day average.
Insiders were net sellers over the 90 days ending Oct 8, 2026; selling is often routine (taxes, diversification).
Heavily shorted, settled Sep 15, 2026, more than a week of normal trading to cover, a crowded exit.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How TSHA is trading
Taysha Gene Therapies, Inc. is +59% over the past year while the S&P 500 is +18%: 40 points ahead of the market.
1-year return · S&P 500 +18%
- vs 200-day average
- −16%
vs 200-day average · a clear downtrend
- RSI (14)
- 34
RSI (14) · neutral
- Below its 52-week high
- 36%
Below its 52-week high
Details›
- Last close2026-10-09
- $4.49
- 1 monthS&P 500 +2.7%
- −13%
- 1 yearS&P 500 +18%
- +59%
- 5 yearsS&P 500 +88%
- −77%
- vs 50-day average$5.49
- −18%
- 52-week high
- $6.98
- 52-week low
- $2.87
- Annualised volatility
- 95%
| Year | Return |
|---|---|
| 2026 (year to date) | −18% |
| 2025 | +218% |
| 2024 | −2.3% |
| 2023 | −22% |
| 2022 | −81% |
| 2021 | −56% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 6 | 0 of 6 | −18% |
| Feb | 6 | 3 of 6 | +9.2% |
| Mar | 6 | 1 of 6 | −10% |
| Apr | 6 | 3 of 6 | +7.9% |
| May | 6 | 2 of 6 | +3.3% |
| Jun | 6 | 2 of 6 | −1.5% |
| Jul | 6 | 3 of 6 | −0.41% |
| Aug | 6 | 5 of 6 | +63% |
| Sep | 6 | 1 of 6 | −9.8% |
| Oct | 7 | 1 of 7 | −4.6% |
| Nov | 6 | 3 of 6 | +14% |
| Dec | 6 | 4 of 6 | −3.4% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.